Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10690328 | 0.84 | LMNA (0.80) | LMNAALDH1A1HRH3KDM4E | |
| SCHEMBL10263723 | 0.84 | POLB (0.58) | ALDH1A1HRH3KDM4ETDP1MEN1 | |
| SCHEMBL14983598 | 0.84 | SIGMAR1 (0.61) | LMNAALDH1A1HRH3KDM4EMEN1 | |
| SCHEMBL10261035 | 0.84 | ALDH1A1 (0.65) | LMNAALDH1A1HRH3KDM4ETDP1 | |
| SCHEMBL14847042 | 0.83 | HRH3 (0.52) | LMNAALDH1A1HRH3KDM4ETDP1 | |
| SCHEMBL19191171 | 0.83 | HRH3 (0.52) | LMNAALDH1A1HRH3KDM4ETDP1 | |
| SCHEMBL27760842 | 0.82 | LMNA (0.57) | LMNAALDH1A1HRH3KDM4EMEN1 | |
| SCHEMBL27760840 | 0.82 | LMNA (0.57) | LMNAALDH1A1HRH3MEN1KMT2A | |
| SCHEMBL23844655 | 0.82 | POLB (0.57) | LMNAALDH1A1HRH3KDM4ETDP1 | |
| SCHEMBL18704971 | 0.82 | MEN1 (0.55) | HRH3KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536175-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | claimed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-2282995-B1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| US-8815901-B2 | Quinoline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2014-08-26 | — | — | US | disclosed |
| US-8674099-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20130324519-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-12-05 | — | — | US | disclosed |
| US-8536175-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| CN-102036963-B | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors | NOVARTIS AG | 2013-08-21 | — | — | CN | disclosed |
| US-20120309741-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120309766-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-07-19 | — | — | US | disclosed |
| US-8030311-B2 | Phenylacetamides suitable as protein kinase inhibitors | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| CN-102036963-A | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors | NOVARTIS AG | 2011-04-27 | — | — | CN | disclosed |
| EP-1874770-B1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| EP-2282995-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| EP-1874770-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | Novartis Pharma AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108640-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | ABL1, NQO2, MAP4K5 | LMNA 2396/4885ALDH1A1 2916/4885HRH3 706/4885 |
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | MAP3K10, MAP3K20, MAP3K9 | LMNA 1846/4885ALDH1A1 3213/4885HRH3 1365/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | LMNA 2810/4885ALDH1A1 2019/4885HRH3 647/4885 |
| US-20130324519-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | LMNA 3052/4885ALDH1A1 3177/4885HRH3 1578/4885 |
| US-20120309766-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | LMNA 3052/4885ALDH1A1 3177/4885HRH3 1578/4885 |
| US-20120309741-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | LMNA 3052/4885ALDH1A1 3177/4885HRH3 1578/4885 |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | MAP3K20, MAP3K10, MAP3K9 | LMNA 1658/4885ALDH1A1 2992/4885HRH3 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.